Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEDI 8367

Next Previous
Drug Profile

MEDI 8367

Alternative Names: MEDI8367

Latest Information Update: 29 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antibodies; Urologics
  • Mechanism of Action Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Renal failure

Most Recent Events

  • 30 Sep 2022 Discontinued - Phase-I for Renal failure (In volunteers) in USA (SC) due to strategic reason (AstraZeneca pipeline, November 2022)
  • 22 Jul 2020 Phase-I clinical trials in Renal failure (In volunteers) in USA (SC) (NCT04365218)
  • 28 Apr 2020 AstraZeneca plans a phase I trial for Renal failure in USA in June 2020 (NCT04365218)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top